The effect of solifenacin treatment for urge urinary incontinence on sexual function in premenopausal and postmenopausal women: a prospective observational study

İpek Merve Evrüke

Article Details

The effect of solifenacin treatment for urge urinary incontinence on sexual function in premenopausal and postmenopausal women: a prospective observational study

Authors:

İpek Merve Evrüke

Publisher:

Cukurova University

Main Topics:

Klinik Tıp Bilimleri

Journal:

Cukurova Medical Journal Vol.48 Issue 1, pp.200-207

Document Type:

Article

Publication Date:

3/2023

Document Language:

English

Document ID (Org No.):

2001282247

pISSN:

2602-3032

Keywords:

Abstract:

 Purpose: The aim of this study is to determine whether solifenacin used for urge urinary incontinence improves sexual function and if so this improvement differs between premenopausal and postmenopausal women. Materials and Methods: 120 women, 48 premenopausal and 72 postmenopausal were enrolled in the study. They filled out the Female Sexual Function Index FSFI before, three months, and six months after the solifenacin 5mg daily treatment for urge urinary incontinence. The results were interpreted in two groups, premenopausal and postmenopausal. The FSFI scores for baseline and for post-treatment were compared for both groups and with each other. Results: All domains of FSFI except orgasm were improved with the use of Solifenacin. The mean FSFI scores following three months n110 and six months n65 of solifenacin treatment are significantly improved compared to the baseline in both premenopausal and postmenopausal patients. This improvement in FSFI scores does not significantly differ between premenopausal and postmenopausal groups. Conclusion: Solifenacin treatment for lower urinary tract symptoms has been shown to have a positive impact on the sexual functions of both premenopausal and postmenopausal women. Although treatment with solifenacin improved sexual dysfunction in women, this improvement did not vary between premenopausal and postmenopausal women.

 Purpose: The aim of this study is to determine whether solifenacin used for urge urinary incontinence improves sexual function and if so this improvement differs between premenopausal and postmenopausal women. Materials and Methods: 120 women, 48 premenopausal and 72 postmenopausal were enrolled in the study. They filled out the Female Sexual Function Index FSFI before, three months, and six months after the solifenacin 5mg daily treatment for urge urinary incontinence. The results were interpreted in two groups, premenopausal and postmenopausal. The FSFI scores for baseline and for post-treatment were compared for both groups and with each other. Results: All domains of FSFI except orgasm were improved with the use of Solifenacin. The mean FSFI scores following three months n110 and six months n65 of solifenacin treatment are significantly improved compared to the baseline in both premenopausal and postmenopausal patients. This improvement in FSFI scores does not significantly differ between premenopausal and postmenopausal groups. Conclusion: Solifenacin treatment for lower urinary tract symptoms has been shown to have a positive impact on the sexual functions of both premenopausal and postmenopausal women. Although treatment with solifenacin improved sexual dysfunction in women, this improvement did not vary between premenopausal and postmenopausal women.

 Purpose: The aim of this study is to determine whether solifenacin used for urge urinary incontinence improves sexual function and if so this improvement differs between premenopausal and postmenopausal women. Materials and Methods: 120 women, 48 premenopausal and 72 postmenopausal were enrolled in the study. They filled out the Female Sexual Function Index FSFI before, three months, and six months after the solifenacin 5mg daily treatment for urge urinary incontinence. The results were interpreted in two groups, premenopausal and postmenopausal. The FSFI scores for baseline and for post-treatment were compared for both groups and with each other. Results: All domains of FSFI except orgasm were improved with the use of Solifenacin. The mean FSFI scores following three months n110 and six months n65 of solifenacin treatment are significantly improved compared to the baseline in both premenopausal and postmenopausal patients. This improvement in FSFI scores does not significantly differ between premenopausal and postmenopausal groups. Conclusion: Solifenacin treatment for lower urinary tract symptoms has been shown to have a positive impact on the sexual functions of both premenopausal and postmenopausal women. Although treatment with solifenacin improved sexual dysfunction in women, this improvement did not vary between premenopausal and postmenopausal women.

 Amaç: Bu çalışmanın amacı urge üriner inkontinans tedavisinde kullanılan solifenasinin cinsel fonksiyonlarda iyileşme sağlayıp sağlamadığını değerlendirmek ve eğer düzelme var ise bunun premenopozal ve postmenopozal kadınlar arasında farklılık gösterip göstermediğini belirlemektir. Gereç ve Yöntem: 48 premenopozal ve 72 postmenopozal olmak üzere 120 kadın hasta çalışmaya dahil edilmiştir. Hastalar urge üriner inkontinans nedenli başlanan 5 mggün solifenasin tedavisinden önce ve tedaviden üç ay ve altı ay sonra Kadın Cinsel İşlev İndeksini FSFI doldurdular. Sonuçlar premenopozal ve postmenopozal olmak üzere iki grupta yorumlandı. Başlangıç ve tedavi sonrası FSFI skorları önce toplam hasta grubunda ve sonrasında gruplar arası karşılaştırıldı. Bulgular: Solifenasin kullanımı ile orgazm hariç tüm FSFI alt gruplarında belirgin iyileşme gözlenmiştir. Üç aylık n110 ve altı aylık n65 solifenasin tedavisini takiben ortalama FSFI skorları hem premenopozal hem de postmenopozal hastalarda başlangıca kıyasla önemli ölçüde iyileşmiştir. FSFI skorlarındaki bu iyileşme premenopozal ve postmenopozal gruplar arasında anlamlı farklılık göstermemiştir. Sonuç: Alt üriner sistem semptomları için başlanan solifenasin tedavisinin hem premenopozal hem de postmenopozal kadınların cinsel fonksiyonları üzerinde olumlu bir etkisi olduğu gösterilmiştir. Solifenasin tedavisi kadınlarda cinsel fonksiyonları iyileştirmesine rağmen, bu iyileşme premenopozal ve postmenopozal kadınlar arasında farklılık göstermemiştir.

Article Details

The effect of solifenacin treatment for urge urinary incontinence on sexual function in premenopausal and postmenopausal women: a prospective observational study

Authors:

İpek Merve Evrüke

Publisher:

Cukurova University

Main Topics:

Klinik Tıp Bilimleri

Journal:

Cukurova Medical Journal Vol.48 Issue 1, pp.200-207

Document Type:

Article

Publication Date:

3/2023

Document Language:

English

Document ID (Org No.):

2001282247

pISSN:

2602-3032

urinary incontinence

sexual dysfunction

FSFI

anticholinergic

solifenacin

Üriner inkontinans

urge; kolinerjik antagonistler; cinsel işlev bozukluğu

fizyolojik

Issues

Article Details

Authors: İpek Merve Evrüke

Publisher: Cukurova University

Main Topics: Klinik Tıp Bilimleri

Journal: Cukurova Medical Journal Vol.48 Issue 1, pp.200-207

Document Type: Article

Publication Date: 3/2023

Document Language: English

Document ID (Org No.): 2001282247

pISSN: 2602-3032

Issues

Authors:

İpek Merve Evrüke

Publisher:

Cukurova University

Main Topics:

Klinik Tıp Bilimleri

Journal:

Cukurova Medical Journal Vol.48 Issue 1, pp.200-207

Document Type:

Article

Publication Date:

3/2023

Document Language:

English

Document ID (Org No.):

2001282247

pISSN:

2602-3032